Healthpeak Properties’ Earnings Call Balances Growth And Risk
Healthpeak Properties, Inc. ((DOC)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healthpeak Properties’ latest earnings call struck a cautiously upbeat tone, with management highlighting strong outpatient medical trends, standout senior housing performance and growing life science leasing momentum. At the same time, they acknowledged headwinds from lab rent pressure, refinancing costs and temporary earnings drag from the Janus Living IPO, framing near-term noise against long-term value creation.
Strong Q1 FFO and Raised 2026 Guidance
Healthpeak reported first‑quarter FFO as adjusted of $0.45 per share and nudged its full‑year 2026 FFO outlook to $1.71–$1.75, implying a midpoint near $1.73. The company underscored confidence in cash flows by repurchasing $100 million of stock in April at an implied FFO yield above 10%, leaning on robust senior housing performance to support the higher bar.
Janus Living IPO: Value Creation and Outperformance
The March IPO of Janus Living emerged as a central value catalyst, with Janus delivering 35% revenue growth and 42% adjusted EBITDA growth in the first quarter. Healthpeak still owns roughly 81.6% of Janus, worth about $5.7 billion, and expects the transaction to be earnings‑neutral in 2026 before turning accretive with around $0.04 per‑share benefit once proceeds are fully deployed.
Outpatient Medical Fundamentals Remain Robust
Outpatient medical continues to be a workhorse, as more than 10 million square feet of renewals since the Physicians merger have posted average cash re‑leasing spreads near 5.8%. In the first quarter alone the segment signed 1.1 million square feet with 79% tenant retention, 91% total occupancy, average 3% rent escalators and modest leasing costs, aided by in‑house efforts that saved about $5 million in commissions.
Blackstone JV and Outpatient Recap Template
Healthpeak closed a recapitalization joint venture with Blackstone on a fully occupied outpatient portfolio at a 6.1% cash cap rate, raising $170 million. Executives described a broader pipeline that could unlock more than $700 million of additional proceeds at cap rates roughly 200 basis points tighter than what the public market currently implies for Healthpeak stock.
Life Science Leasing Momentum and Occupancy Improvement
In life science, signs of gradual healing appeared as total occupancy ticked up to 77.7% and 141,000 square feet of leases were executed in the quarter, 92% of which were new tenants. With about 355,000 square feet under LOI, mostly new leasing on vacant space and including several large deals, management guided to at least a 100‑basis‑point occupancy gain versus year‑end 2025.
Gateway Acquisition and Early Leasing Wins
The Gateway acquisition in South San Francisco, completed at what management called attractive pricing, is already showing traction. The property has 62,000 square feet of signed leases or LOIs in hand plus another 113,000 square feet in active proposals and tours, with achieved rents at or above underwriting and positioned to drive earnings in 2027 and beyond.
Senior Housing Operating Performance and Capital Deployment
Senior housing remains a key growth engine, with entry fees hitting an all‑time first‑quarter high and a sizable acquisition program already underway. Healthpeak invested about $714 million into on‑balance‑sheet senior housing assets before the Janus IPO and expects this portfolio, generating roughly $240 million of current‑year FFO, to deliver strong returns that help offset IPO‑related earnings drag.
Balance Sheet and Liquidity Actions
The balance sheet came into focus with net debt‑to‑EBITDA at about 5.4 times, supported by active capital recycling. During the quarter Healthpeak repaid $103 million of secured mortgages, lined up a $400 million undrawn delayed‑draw term loan and executed a $100 million buyback, pacing toward roughly $1 billion of recaps and sales matched by about $1 billion of acquisitions.
Development and Entitlement Progress
On the development front the mixed‑use Alewife project advanced, gaining initial planning board approval that sets up a path toward full entitlements by late 2026. With Hines slated as multifamily partner, Healthpeak is targeting a potential residential groundbreaking around 2027, framing Alewife as a long‑dated but meaningful option on future growth.
Lab Re-leasing Spread Softness This Quarter
Despite improving occupancy, lab re‑leasing economics showed some strain, with quarterly cash re‑leasing spreads slipping to about 3.5% versus a 12‑month average near 5%. Management tied the softness to broader market pressure and noted that peers are reporting tougher leasing dynamics as well, suggesting that some rent headwinds may persist in select submarkets.
Life Science Vacancy and Near-Term Move-Outs
Life science still contends with meaningful vacancy, starting from a 77.7% occupancy level and facing around 400,000 square feet of expirations in 2026. While roughly half a million square feet of commencements should help offset, and management expects net absorption over time, an additional 50,000 square feet of expected move‑outs midyear keeps near‑term churn on investors’ radar.
Temporary Earnings Drag from the Janus IPO
Management emphasized that the Janus Living IPO initially brings some earnings drag due to higher public company costs and idle cash awaiting deployment. They reiterated, however, that the structure is designed to be roughly neutral in 2026 and accretive thereafter, with long‑term earnings uplift hinging on efficiently putting IPO proceeds to work.
Refinancing and Interest Rate Headwinds
Refinancing needs are another source of pressure as $650 million of senior notes mature in June, raising expected interest expense by about $20 million this year. General and administrative costs are seen running roughly $5 million higher as well, which will likely weigh on near‑term earnings even as underlying property performance trends remain solid.
Conservative Same-Store NOI and Modest Guidance Lift
Even with better leasing activity, Healthpeak left its same‑store NOI outlook essentially unchanged and lifted full‑year FFO guidance by only a penny. Executives framed the caution as a function of deal sequencing, acquisition timing and refinancing costs, a stance some investors may interpret as sandbagging given the $0.45 first‑quarter FFO run rate.
Market-Specific Headwinds in Boston
By market, Boston stood out as the most challenged life science region in the portfolio, with a supply‑demand imbalance requiring a more selective approach to leasing. Management did point to improving signs in West Cambridge, but stressed that overall Boston dynamics remain mixed and warrant careful submarket targeting.
Forward-Looking Guidance and Strategic Outlook
Looking ahead, Healthpeak’s guidance calls for 2026 FFO as adjusted of $1.71–$1.75 per share alongside unchanged same‑store NOI assumptions and higher expected interest and G&A costs. The company plans to deploy roughly $750 million of cash into acquisitions by year‑end and anticipates at least a 100‑basis‑point improvement in life science occupancy, supporting its view that today’s disciplined capital allocation will translate into future earnings growth.
Healthpeak’s call painted a picture of a diversified healthcare REIT leaning into strong outpatient and senior housing fundamentals while patiently working through life science and financing headwinds. For investors, the message was one of near‑term caution but growing confidence that the Janus IPO, capital recycling and targeted acquisitions will compound value over the next several years.
